Jane Street Group LLC Cuts Position in Protalix BioTherapeutics, Inc. (NYSE:PLX)

Jane Street Group LLC lessened its stake in Protalix BioTherapeutics, Inc. (NYSE:PLX) by 84.2% during the third quarter, HoldingsChannel reports. The firm owned 45,952 shares of the company’s stock after selling 244,307 shares during the period. Jane Street Group LLC’s holdings in Protalix BioTherapeutics were worth $47,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of PLX. Cubist Systematic Strategies LLC bought a new position in shares of Protalix BioTherapeutics in the second quarter worth $37,000. Squarepoint Ops LLC boosted its position in Protalix BioTherapeutics by 673.3% during the second quarter. Squarepoint Ops LLC now owns 137,764 shares of the company’s stock valued at $161,000 after buying an additional 119,949 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Protalix BioTherapeutics during the second quarter worth about $80,000. AQR Capital Management LLC purchased a new stake in shares of Protalix BioTherapeutics during the second quarter worth about $67,000. Finally, GSA Capital Partners LLP lifted its holdings in Protalix BioTherapeutics by 8.5% in the third quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock worth $444,000 after buying an additional 33,969 shares during the period. Institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Stock Down 0.5 %

Shares of NYSE PLX opened at $2.17 on Thursday. Protalix BioTherapeutics, Inc. has a twelve month low of $0.82 and a twelve month high of $2.36. The firm has a market cap of $159.79 million, a P/E ratio of -16.69 and a beta of 0.71. The company has a 50 day moving average of $1.76 and a 200 day moving average of $1.31.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Protalix BioTherapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, December 12th.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.